UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.005

Sortiert nach

Which threshold for ER positivity? a retrospective study based on 9639 patients

Annals of oncology, 2014-05, Vol.25 (5), p.1004-1011

2014

Volltextzugriff (PDF)

Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer

Annals of oncology, 2009-06, Vol.20 (6), p.993-999

Buzdar, A. U

2009

Volltextzugriff (PDF)

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

The lancet oncology, 2006-08, Vol.7 (8), p.633-643

2006

Volltextzugriff (PDF)

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

The Lancet (British edition), 2002-06, Vol.359 (9324), p.2131-2139

2002

Volltextzugriff (PDF)

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

Annals of oncology, 2007-12, Vol.18 (12), p.1927-1934

2007

Volltextzugriff (PDF)

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer

Annals of oncology, 2013-08, Vol.24 (8), p.1999-2004

2013

Volltextzugriff (PDF)

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial

Annals of oncology, 2017-05, Vol.28 (5), p.1070-1077

2017

Volltextzugriff (PDF)

Anastrozole Alone or in combination with Tamoxifen versus Tamoxifen Alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in combination) trial efficacy and safety update analyses

Cancer, 2003-11, Vol.98 (9), p.1802-1810

2003

Volltextzugriff (PDF)

Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial

Journal of clinical oncology, 2000-11, Vol.18 (22), p.3758-3767

2000

Volltextzugriff (PDF)

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial

Journal of clinical oncology, 2002-08, Vol.20 (16), p.3386-3395

2002

Volltextzugriff (PDF)

Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate

Journal of clinical oncology, 2001-07, Vol.19 (14), p.3357-3366

2001

Volltextzugriff (PDF)

Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

Journal of clinical oncology, 1999-02, Vol.17 (2), p.460-469

1999

Volltextzugriff (PDF)

Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer

Journal of clinical oncology, 1999-02, Vol.17 (2), p.485-493

1999

Volltextzugriff (PDF)

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

Journal of clinical oncology, 1996-08, Vol.14 (8), p.2197-2205

1996

Volltextzugriff (PDF)

Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers

Annals of oncology, 2007-05, Vol.18 (5), p.874-880

2007

Volltextzugriff (PDF)

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)

Breast cancer research and treatment, 2017-01, Vol.161 (2), p.363-373

2017

Volltextzugriff (PDF)

Locoregional Recurrence Patterns After Mastectomy and Doxorubicin-Based Chemotherapy: Implications for Postoperative Irradiation

Journal of clinical oncology, 2000-08, Vol.18 (15), p.2817-2827

2000

Volltextzugriff (PDF)

Endocrine therapy in the treatment of metastatic breast cancer

Seminars in oncology, 2001-06, Vol.28 (3), p.291-304

Buzdar, Aman U

2001

Volltextzugriff (PDF)

The sequential use of endocrine treatment for advanced breast cancer: where are we?

Annals of oncology, 2012-06, Vol.23 (6), p.1378-1386

2012

Volltextzugriff (PDF)

Advances in aromatase inhibition : Clinical efficacy and tolerability in the treatment of breast cancer

Clinical cancer research, 2001-09, Vol.7 (9), p.2620-2635

2001

Volltextzugriff (PDF)

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer

Annals of oncology, 2012-03, Vol.23 (3), p.589-597

2012

Volltextzugriff (PDF)

Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab

Annals of oncology, 2008-12, Vol.19 (12), p.2020-2025

2008

Volltextzugriff (PDF)

Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

European journal of cancer (1990), 2003-08, Vol.39 (12), p.1684-1689

2003

Volltextzugriff (PDF)

Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers

British journal of cancer, 2008-07, Vol.99 (1), p.68-71

2008

Volltextzugriff (PDF)

Management of Breast Cancer During Pregnancy Using a Standardized Protocol

Journal of clinical oncology, 1999-03, Vol.17 (3), p.855-861

1999

Volltextzugriff (PDF)

1 – 25 von 1.005

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(895)
Mit Volltextzugriff
(881)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(600)
Humans
(588)
Life Sciences & Biomedicine
(558)
Female
(520)
Oncology
(424)
Breast Neoplasms - Drug Therapy
(402)
Middle Aged
(355)
Biological And Medical Sciences
(321)
Medical Sciences
(315)
Adult
(279)
Aged
(261)
Breast Neoplasms - Pathology
(208)
Chemotherapy
(178)
Pharmacology. Drug Treatments
(178)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(174)
Antineoplastic Agents
(165)
Tumors
(152)
Breast Cancer
(143)
Gynecology. Andrology. Obstetrics
(111)
Breast Neoplasms - Mortality
(109)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Which threshold for ER positivity? a retrospective study based on 9639 patients

Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial

Anastrozole Alone or in combination with Tamoxifen versus Tamoxifen Alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in combination) trial efficacy and safety update analyses

Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial

Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate

Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)

Locoregional Recurrence Patterns After Mastectomy and Doxorubicin-Based Chemotherapy: Implications for Postoperative Irradiation

Endocrine therapy in the treatment of metastatic breast cancer

The sequential use of endocrine treatment for advanced breast cancer: where are we?

Advances in aromatase inhibition : Clinical efficacy and tolerability in the treatment of breast cancer

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer

Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab

Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers

Management of Breast Cancer During Pregnancy Using a Standardized Protocol

Suchergebnisse filtern